|
1
|
Helmick CG, Felson DT, Lawrence RC,
Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremers HM, Mayes MD,
Merkel PA, et al: Estimates of the prevalence of arthritis and
other rheumatic conditions in the United States. Part I. Arthritis
Rheum. 58:15–25. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Peng SL: Altered T and B lymphocyte
signaling pathways in lupus. Autoimmun Rev. 8:179–183. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hogan J and Radhakrishnan J: The treatment
of minimal change disease in adults. J Am Soc Nephrol. 24:702–711.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bertsias G, Gordon C and Boumpas DT:
Clinical trials in systemic lupus erythematosus (SLE): Lessons from
the past as we proceed to the future-the EULAR recommendations for
the management of SLE and the use of end-points in clinical trials.
Lupus. 17:437–442. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ceman S and Saugstad J: MicroRNAs:
Meta-controllers of gene expression in synaptic activity emerge as
genetic and diagnostic markers of human disease. Pharmacol Ther.
130:26–37. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lorenzen JM, Haller H and Thum T:
MicroRNAs as mediators and therapeutic targets in chronic kidney
disease. Nat Rev Nephrol. 7:286–294. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Farris AB and Colvin RB: Renal
interstitial fibrosis: Mechanisms and evaluation. Curr Opin Nephrol
Hypertens. 21:289–300. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang G, Kwan BC, Lai FM, Choi PC, Chow KM,
Li PK and Szeto CC: Intrarenal expression of miRNAs in patients
with hypertensive nephrosclerosis. Am J Hypertens. 23:78–84. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang G, Kwan BC, Lai FM, Choi PC, Chow KM,
Li PK and Szeto CC: Intrarenal expression of microRNAs in patients
with IgA nephropathy. Lab Invest. 90:98–103. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chung AC, Huang XR, Meng X and Lan HY:
miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. J Am Soc
Nephrol. 21:1317–1325. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kato M, Zhang J, Wang M, Lanting L, Yuan
H, Rossi JJ and Natarajan R: MicroRNA-192 in diabetic kidney
glomeruli and its function in TGF-beta-induced collagen expression
via inhibition of E-box repressors. Proc Natl Acad Sci USA.
104:3432–3437. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Putta S, Lanting L, Sun G, Lawson G, Kato
M and Natarajan R: Inhibiting microRNA-192 ameliorates renal
fibrosis in diabetic nephropathy. J Am Soc Nephrol. 23:458–469.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dai Y, Sui W, Lan H, Yan Q, Huang H and
Huang Y: Comprehensive analysis of microRNA expression patterns in
renal biopsies of lupus nephritis patients. Rheumatol Int.
29:749–754. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu J, Kwan BC, Lai FM, Tam LS, Li EK, Chow
KM, Wang G, Li PK and Szeto CC: Glomerular and tubulointerstitial
miR-638, miR-198 and miR-146a expression in lupus nephritis.
Nephrology (Carlton). 17:346–351. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rabinovitch MB, Liberman and Fausto N:
Plasma ribonuclease activity in human uremia. J Lab Clin Med.
53:563–568. 1959.PubMed/NCBI
|
|
16
|
Neal CS, Michael MZ, Pimlott LK, Yong TY,
Li JY and Gleadle JM: Circulating microRNA expression is reduced in
chronic kidney disease. Nephrol Dial Transplant. 26:3794–3802.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang W, Mou S, Wang L, Zhang M, Shao X,
Fang W, Lu R, Qi C, Fan Z, Cao Q, et al: Up-regulation of serum
MiR-130b-3p level is associated with renal damage in early lupus
nephritis. Sci Rep. 5:126442015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tan W, Gu Z, Shen B, Jiang J, Meng Y, Da
Z, Liu H, Tao T and Cheng C: PTEN/Akt-p27(kip1) signaling promote
the BM-MSCs senescence and apoptosis in SLE patients. J Cell
Biochem. 116:1583–1594. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tan EM, Cohen AS, Fries JF, Masi AT,
McShane DJ, Rothfield NF, Schaller JG, Talal N and Winchester RJ:
The 1982 revised criteria for the classification of systemic lupus
erythematosus. Arthritis Rheum. 25:1271–1277. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lamb EJ, Webb MC and O'Riordan SE: Using
the modification of diet in renal disease (MDRD) and Cockcroft and
Gault equations to estimate glomerular filtration rate (GFR) in
older people. Age Ageing. 36:689–692. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lv C, Zhou YH, Wu C, Shao Y, Lu CL and
Wang QY: The changes in miR-130b levels in human serum and the
correlation with the severity of diabetic nephropathy. Diabetes
Metab Res Rev. 31:717–724. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Colangelo T, Fucci A, Votino C, Sabatino
L, Pancione M, Laudanna C, Binaschi M, Bigioni M, Maggi CA, Parente
D, et al: MicroRNA-130b promotes tumor development and is
associated with poor prognosis in colorectal cancer. Neoplasia.
15:1086–1099. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Egawa H, Jingushi K, Hirono T, Ueda Y,
Kitae K, Nakata W, Fujita K, Uemura M, Nonomura N and Tsujikawa K:
The miR-130 family promotes cell migration and invasion in bladder
cancer through FAK and Akt phosphorylation by regulating PTEN. Sci
Rep. 6:205742016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Han X, Wang Y, Zhang X, Qin Y, Qu B, Wu L,
Ma J, Zhou Z, Qian J, Dai M, et al: MiR-130b ameliorates murine
lupus nephritis through targeting type I interferon pathway on
resident renal cells. Arthritis Rheumatol. 68:2232–2243. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Govender D and Chetty R: Gene of the
month: PTEN. J Clin Pathol. 65:601–603. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li DM and Sun H: TEP1, encoded by a
candidate tumor suppressor locus, is a novel protein tyrosine
phosphatase regulated by transforming growth factor beta. Cancer
Res. 57:2124–2129. 1997.PubMed/NCBI
|
|
28
|
Di Cristofano A and Pandolfi PP: The
multiple roles of PTEN in tumor suppression. Cell. 100:387–390.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xu WT, Yang Z and Lu NH: Roles of PTEN
(Phosphatase and Tensin Homolog) in gastric cancer development and
progression. Asian Pac J Cancer Prev. 15:17–24. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Myers MP and Tonks NK: PTEN: Sometimes
taking it off can be better than putting it on. Am J Hum Genet.
61:1234–1238. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ye B, Jiang LL, Xu HT, Zhou DW and Li ZS:
Expression of PI3K/AKT pathway in gastric cancer and its blockade
suppresses tumor growth and metastasis. Int J Immunopathol
Pharmacol. 25:627–636. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu XN, Ye YX, Niu JW, Li Y, Li X, You X,
Chen H, Zhao LD, Zeng XF, Zhang FC, et al: Defective PTEN
regulation contributes to B cell hyperresponsiveness in systemic
lupus erythematosus. Sci Transl Med. 6:246ra992014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kaplan MJ: Apoptosis in systemic lupus
erythematosus. Clin Immunol. 112:210–218. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Seery JP, Cattell V and Watt FM: Cutting
edge: Amelioration of kidney disease in a transgenic mouse model of
lupus nephritis by administration of the caspase inhibitor
carbobenzoxy-valyl-alanyl-aspartyl-(beta-o-methyl)-fluoromethylketone.
J Immunol. 167:2452–2455. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nakajima A, Hirai H, Kayagaki N, Yoshino
S, Hirose S, Yagita H and Okumura K: Treatment of lupus in NZB/W F1
mice with monoclonal antibody against Fas ligand. J Autoimmun.
14:151–157. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schaub FJ, Han DK, Liles WC, Adams LD,
Coats SA, Ramachandran RK, Seifert RA, Schwartz SM and Bowen-Pope
DF: Fas/FADD-mediated activation of a specific program of
inflammatory gene expression in vascular smooth muscle cells. Nat
Med. 6:790–796. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lenda DM, Kikawada E, Stanley ER and
Kelley VR: Reduced macrophage recruitment, proliferation, and
activation in colony-stimulating factor-1-deficient mice results in
decreased tubular apoptosis during renal inflammation. J Immunol.
170:3254–3262. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Scheid MP and Woodgett JR: Unravelling the
activation mechanisms of protein kinase B/Akt. FEBS Lett.
546:108–112. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Deane JA and Fruman DA: Phosphoinositide
3-kinase: Diverse roles in immune cell activation. Annu Rev
Immunol. 22:563–598. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cantley LC and Neel BG: New insights into
tumor suppression: PTEN suppresses tumor formation by restraining
the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA.
96:4240–4245. 1999. View Article : Google Scholar : PubMed/NCBI
|
